NasdaqGM:ATAIPharmaceuticals
Is Psychedelic Nasal Spray Data And Index Inclusion Altering The Investment Case For AtaiBeckley (ATAI)?
AtaiBeckley Inc. recently reported peer-reviewed Phase 2a data showing that a single 10 mg dose of its intranasal psychedelic candidate BPL-003 produced rapid, sustained improvements in treatment-resistant depression with favorable tolerability, while also securing FDA alignment to begin Phase 3 trials and gaining inclusion in several major U.S. equity benchmark indices.
The combination of promising long-lasting clinical effects from a short-acting psychedelic nasal spray and entry into...